2-NMC Stats & Data

• Synthetic cathinones are often mis‑sold or used to adulterate other stimulants; EUDA explicitly notes mis‑selling of cathinones as amphetamine/MDMA/cocaine. Use multi‑reagent testing and—ideally—laboratory drug checking to confirm identity and detect adulterants.

• Virtually no controlled pharmacology on 2‑NMC; harm profile inferred from close analogues (e.g., mephedrone, 3‑MMC) and user reports. Expect dopamine/noradrenaline transporter inhibition > serotonin, implying euphoria with significant cardiovascular strain.

• Hyperthermia, dehydration, and hyponatraemia are documented risks with empathogenic cathinones; prefer small, regular sips of isotonic fluids and salty snacks rather than excessive water. Take cool‑down breaks away from heat and vigorous activity.

• Repeated or high cumulative dosing increases vasoconstriction risk (cold/blue extremities), blood pressure elevation, and chest discomfort; seek medical care for chest pain, confusion, or overheating.

• Nasal use causes notable mucosal irritation for many cathinones; oral dosing is less locally damaging and often smoother. If snorting, use tiny lines and saline rinse afterward.

• Vaporizing unknown powders increases exposure to irritating/unknown pyrolysis products and can drive compulsive redosing; avoid when possible.

• Compulsive redosing and sleep loss markedly amplify anxiety, paranoia and psychosis risk; set a firm session cap, stop redosing at least 6–8 h before planned sleep, and prioritize recovery nutrition, electrolytes, and sleep hygiene.

• Because mislabeling of “3‑MMC/4‑MMC” as other cathinones is common in current markets, do not assume subjective effects confirm identity—lab results regularly reveal substitutions (e.g., 2‑MMC, 3‑CMC, dipentylone).